A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
A team of investigators sought to determine if treatment efficacy can be maintained without radiotherapy among patients with newly diagnosed, early-stage, unfavorable Hodgkin lymphoma.
Researchers sought to determine whether R-MegaCHOEP would improve outcomes compared to R-CHOEP-14 in patients with newly diagnosed, aggressive B-cell lymphoma.
A team of investigators sought to assess the safety and efficacy of lenalidomide plus R-CHOP in patients with previously untreated activated B-cell-like subtype of diffuse large B-cell lymphoma.
Investigators assessed outcomes following a radiotherapy dose of 4 Gy in 2 fractions vs 24 Gy in 12 fractions in patients with follicular lymphoma or marginal zone lymphoma.
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
Investigators of a phase 3 trial will compare epcoritamab with investigator’s choice of chemotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
The approval was based on data from an open-label phase 1/2 trial in patients aged 1 to 21 years that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least 1 systemic treatment.
Experts discuss clinical, pathologic, and genomic features of Burkitt lymphoma in adults, as well as standard and emerging treatment options for this patient population.
Loncastuximab tesirine is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine dimer cytotoxin.
Adults treated for Hodgkin lymphoma have an increased risk of death from heart disease, interstitial lung disease, infections, and adverse effects of therapy.
Depending on the type and stage of lymphoma, physicians may choose to avoid having their patients undergo radiation therapy for fear of potential toxic effects in organs.
Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.
Exposure to doxorubicin during treatment for DLBCL was linked to a higher risk for cardiovascular diseases, highlighting the need for early cardiac surveillance.
Among patients with early-stage, favorable Hodgkin lymphoma, treatment regimens with conventional chemotherapy may be effective in a subset of patients.
Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
In this study, researchers determined that the quantity and quality of discussions regarding survivorship and late effects of treatment between AYA lymphoma survivors and their oncologists is improving, but survivorship information is still lacking.
